Midazolam Sedation for Neonatal Lumbar Puncture

This study has been terminated.
Information provided by (Responsible Party):
i_shavit, Rambam Health Care Campus
ClinicalTrials.gov Identifier:
First received: July 18, 2009
Last updated: May 5, 2014
Last verified: July 2010
Lumbar puncture is one of the most common painful procedures performed on neonates in the Emergency Department (ED). The investigators will study in a randomized controlled trial, the efficacy of intravenous administration of a single dose of Midazolam in reducing pain and anxiety in neonates undergoing lumbar puncture in the ED, as well as the rate of adverse sedation reactions. The investigators hypothesize that compared with placebo, single dose Midazolam would significantly decrease pain and anxiety and will have low rate of adverse reactions.

Condition Intervention Phase
Drug: Midazolam
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Midazolam Sedation for Neonatal Lumbar Puncture in the Emergency Department: A Randomized Controlled Trial

Resource links provided by NLM:

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • The Simplified Neonatal Facial Coding System will be used for assessment of pain. Scoring will be composed from four specific facial actions (brow bulge, nasolabial furrow, eye squeeze, and open mouth) and the presence or absence of crying [ Time Frame: 20 seconds prior lumbar puncture, during needle insertion, and 20 seconds post insertion ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Physician's level of satisfaction from the procedural conditions [ Time Frame: Five minutes post successful LP ] [ Designated as safety issue: Yes ]
  • LP Success rate [ Time Frame: Five minutes post successful LP ] [ Designated as safety issue: Yes ]
  • Adverse sedation reactions [ Time Frame: During procedure and during recovery phase ] [ Designated as safety issue: Yes ]

Enrollment: 12
Study Start Date: July 2009
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Midazolam
Administration of Midazolam prior Lumbar Puncture
Drug: Midazolam
Intravenous infusion of 0.05 mg/kg of Midalolam


Ages Eligible for Study:   up to 30 Days
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • American Society of Anesthesiologists (ASA) score I, II
  • Post natal age ≤ 30 days
  • Fasting of at least 2 hours before the procedure

Exclusion Criteria:

  • American Society of Anesthesiologists (ASA) score III or greater
  • Gestational age of 37 weeks or younger
  • Congenital disease or defect
  • Any medication provided by the caregiver prior ED admission
  • Fasting of less than 2 hours
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00942539

Rambam Health Care Campus
Haifa, Israel
Sponsors and Collaborators
Rambam Health Care Campus
Principal Investigator: Itai Shavit, MD Rambam Health Care Campus
  More Information

No publications provided

Responsible Party: i_shavit, Pediatric Emergency Department director, Rambam Health Care Campus
ClinicalTrials.gov Identifier: NCT00942539     History of Changes
Other Study ID Numbers: 2958CTIL 
Study First Received: July 18, 2009
Last Updated: May 5, 2014
Health Authority: Israel: Ministry of Health

Keywords provided by Rambam Health Care Campus:

Additional relevant MeSH terms:
Adjuvants, Anesthesia
Anesthetics, General
Anesthetics, Intravenous
Anti-Anxiety Agents
Central Nervous System Agents
Central Nervous System Depressants
GABA Agents
GABA Modulators
Hypnotics and Sedatives
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents

ClinicalTrials.gov processed this record on February 11, 2016